Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials

Lefamulin was the first systemic pleuromutilin antibiotic approved for intravenous and oral use in adults with community-acquired bacterial pneumonia based on two phase 3 trials (Lefamulin Evaluation Against Pneumonia [LEAP]-1 and LEAP-2). This pooled analysis evaluated lefamulin efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Paukner, Susanne, Mariano, David, Das, Anita F., Moran, Gregory J., Sandrock, Christian, Waites, Ken B., File, Thomas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698636/
https://www.ncbi.nlm.nih.gov/pubmed/34943700
http://dx.doi.org/10.3390/antibiotics10121489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698636/
https://www.ncbi.nlm.nih.gov/pubmed/34943700
http://dx.doi.org/10.3390/antibiotics10121489

Ejemplares similares